FLEX Technology Designed to Enhance the Patient Experience

Surgeon Training Underway for the Initial Launch of the Lap-Band^® 2.0 FLEX

IRVINE, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences^® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Adam Smith, D.O., Bariatric Surgery Specialist and Chief Executive Officer of Ultimate Bariatrics in Dallas, Fort Worth, TX, and Christine Ren-Fielding, M.D., Professor of Surgery at NYU Grossman School of Medicine, Director of NYU Langone Health’s Weight Management Program and Chief of the Division of Bariatric Surgery, have successfully performed the first surgeries utilizing the company’s next generation, enhanced Lap-Band^® 2.0 FLEX.

“The first surgeries utilizing the Lap-Band^® 2.0 FLEX mark, not only a seminal moment in the company’s launch of this enhanced product, but also a leap forward in improving the Lap-Band^® patient experience,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. “We are excited to begin our initial launch of the Lap-Band^® 2.0 FLEX that will ultimately demonstrate the real-world benefits of the new FLEX technology, which acts as a relief valve, to alleviate discomfort from swallowing large pieces of food, eliminating the need for in-office band adjustments. We believe, based on current surgeon feedback, that the Lap-Band^® 2.0 FLEX will lead to increased demand for Lap-Band^® surgery and will become a growth catalyst the Lap-Band^® franchise and the company.”

Dr. Smith, a veteran surgeon utilizing the Lap-Band^® system and Lap-Band^® patient, shared his anticipation and positive outlook on the Lap-Band^® 2.0 FLEX, “As a long-time practitioner of the Lap-Band^® System, I have anticipated utilizing the Lap-Band^® 2.0 FLEX with great interest. I believe it will improve the patient experience by minimizing the need for manual band adjustments, especially when related to the urgent need to relieve food obstructions. Specifically, pieces of food that were once too large to pass through the narrowed passage can now pass through easily because of the new FLEX technology, since it allows the band to relax momentarily and then return to its resting diameter. This ability for self-correction makes the Lap-Band^® 2.0 FLEX a better long-term weight loss solution for my patients and I look forward to increasing its usage in my practice, going forward.”

About ReShape Lifesciences^®
ReShape Lifesciences^® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band^® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon^® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.

Forward-Looking Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include the statements that we expect that the Lap-Band^® 2.0 FLEX will lead to increased demand for Lap-Band^® surgery and will become a growth catalyst for the company. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission, including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.

CONTACTS
ReShape Lifesciences Investor Contact:
Paul F. Hickey
President and Chief Executive Officer
949-276-7223
ir@ReShapeLifesci.com

Investor Relations Contact:
Rx Communications Group
Michael Miller
(917)-633-6086
mmiller@rxir.com